HMy2.CIR [C1R, HMy2.C1R] (ATCC® CRL-1993)

Organism: Homo sapiens, human  /  Cell Type: B lymphoblast

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Organism Homo sapiens, human
Cell Type B lymphoblast
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells contain Eptein-Barr Viral DNA sequences
Applications
Since the HMy2.CIR cell line was derived from the HMy.
The CRL-1621cell line is reported to be positive for Epstein-Barr nuclear antigen (EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +).
B lymphoblastoid cell line, a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), by gamma irradiation and selection for loss of HLA class I antigen expression.
The HMy2.CIR cell line was derived from the HMy.
The cells are useful as host for transfected class I major histocompatibility antigen genes.
Storage Conditions liquid nitrogen vapor phase
Derivation
The CRL-1621cell line is reported to be positive for Epstein-Barr nuclear antigen (EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +). Since the HMy2.CIR cell line was derived from the HMy.2 B lymphoblastoid cell line, a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), it is assumed to be EBNA positive.
The HMy2.CIR cell line was derived from the HMy.2 B lymphoblastoid cell line, a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), by gamma irradiation and selection for loss of HLA class I antigen expression.
Comments
The CRL-1621cell line is reported to be positive for Epstein-Barr nuclear antigen (EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +). Since the HMy2.CIR cell line was derived from the HMy.2 B lymphoblastoid cell line, a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), it is assumed to be EBNA positive.
The HMy2.CIR cell line was derived from the HMy.2 B lymphoblastoid cell line, a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), by gamma irradiation and selection for loss of HLA class I antigen expression.
The cells express no HLA A or B locus products, but do express small amounts of HLA Cw4.
The cells are useful as host for transfected class I major histocompatibility antigen genes.
Subculturing
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10(5) viable cells/ml.
Interval: Maintain between 2 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
STR Profile
Amelogenin: X
CSF1PO: 6,10
D13S317: 11,13
D16S539: 9,13
D5S818: 10,13
D7S820: 7,12
THO1: 8
TPOX: 8
vWA: 17
Name of Depositor P Cresswell
References

Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569